← All trials
NCT05343871
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 5, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- Apr 25, 2022
- Last posted
- Jul 27, 2022
- Enrollment
- 2880
- Arms / groups
- 21 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Albert B. Sabin Vaccine InstituteLead sponsor
- Stanford UniversityCollaborator
- Aga Khan UniversityCollaborator
- Oswaldo Cruz FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.